Published in:
01-05-2014 | Original Article
Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations
Published in: Supportive Care in Cancer | Issue 5/2014
Login to get accessAbstract
Purpose
Chemotherapy-induced peripheral neuropathy (CIPN) is increasing with introduction of new and combination cancer pharmacotherapies. This study evaluated associations between clinical and self-report measurements and current perception threshold (CPT), a neuroselective measure of sensory nerve function that may detect asymptomatic CIPN damage.
Methods
Data for this secondary analysis were from a prospective, observational study using CPT to evaluate CIPN. Bivariate mixed models, accounting for the intraclass correlation between repeated patient assessments, were used to assess the relationship between CPT at each frequency (5, 250, and 2,000 Hz) and each subjective measure (Neuropathic Pain Scale, FACT-GOGntx) and objective measurement (quantitative sensory testing, deep tendon reflexes, and grip strength).
Results
A total of 29 chemotherapy-naïve subjects with various cancer types had a mean age of 56.7 (SD 10.4); nine subjects developed CIPN grade >1 using NCI CTC-AE criteria. Cold detection thresholds were inversely associated with CPT 5 [b(95 % CI) = −2.5(−4.5, −0.5)] and CPT 2,000 [−7.5(−11.8, −3.3)] frequencies. FACT GOG-ntx quality of life (QoL) scale and neurotoxicity and function subscales were inversely associated with CPT 2,000 [−1.8 (−3.5, −0.05), −2.2 (−4.2, −0.2), and −5.4 (−9.8, −0.9), respectively], indicating worsening QoL, impairment, and function as hypoesthesia increases.
Conclusions
CPT 2,000 may identify impending worsening of patient-reported outcomes such as QoL.